Luke
Analyst
on behalf of Brian Skorney)
Analyst
Barclays
Equibles does not estimate personal net worth.
About Luke
Luke is recorded as Analyst at on behalf of Brian Skorney) and Analyst at Barclays. Luke has spoken on 3 earnings calls and 1 other investor event across 4 companies, most recently for Scholar Rock Holding Corp on August 6, 2026. Those appearances were for Scholar Rock Holding Corp (SRRK), Exelixis, Inc. (EXEL), Vir Biotechnology, Inc. (VIR) and Relay Therapeutics, Inc. (RLAY). The companies whose calls Luke spoke on are classified in the Healthcare sector.
Luke on recent calls
“Are you seeing any payer signal that they'll impose time limits or require a re-review of benefit after a shorter initial authorization? Thank you.”
“You've previously talked about potentially partnering ZANZO in the same way that you did Cabo. Are you still looking to pursue that, or are you going to try and keep Zanza internal globally?”
“For HDV, with the Eclipse 1 trial reading out in 4Q and then you have Eclipse 2 and 3 reading out in 1Q next year, how are you guys thinking about assuming a positive Eclipse 1 trial?”
“And then last for me, it looks like the rash for the triplet is a new signal compared to the doublet data. Could you comment on the presentation and management of that AE?”
Affiliation history
-
on behalf of Brian Skorney)
Analyst
Source not stated
Current -
Barclays
Analyst
Source not stated
Current
Company network
Exelixis, Inc.
EXEL
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-08-05
View calls and events